Malignant rhabdoid tumor of adrenal gland

2002 ◽  
Vol 39 (2) ◽  
pp. 128-131 ◽  
Author(s):  
Nilgün Yaris ◽  
Umit Cobanoglu ◽  
Embiya Dilber ◽  
Ali Ahmetoğlu ◽  
Haluk Saruhan ◽  
...  
2021 ◽  
pp. 106689692110243
Author(s):  
Murad Alturkustani ◽  
Ryan Schmidt ◽  
Christopher Gayer ◽  
Mikako Warren ◽  
Fariba Navid ◽  
...  

Malignant rhabdoid tumor (MRT) is a rare, SWItch/sucrose nonfermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 ( SMARCB1)-deficient, aggressive tumor, occurring predominantly in children below 3 years of age. Primary adrenal MRT is extremely rare, with only 3 cases reported in the literature. A previously healthy 14-year-old female presented with left upper quadrant/epigastric abdominal pain. Imaging studies revealed an 8.0 × 8.0 × 6.5 cm, heterogeneous, partially enhancing mass along the superior margin of the left kidney encasing the adrenal gland. Surgical resection of the tumor revealed a hypercellular heterogeneous neoplasm arising from the adrenal gland. It was composed predominantly of primitive small round blue cells with focal true rosettes and areas of vague glandular epithelial differentiation and chondroid differentiation. Classic rhabdoid-type cytoplasmic inclusions were focally present. Mitoses, tumor necrosis, and hemorrhage were readily seen. Tumor cells showed complete loss of SMARCB1 (INI1) nuclear staining, demonstrated strong, and diffuse positivity for glypican 3, patchy positivity for CD99, cytokeratin, Sal-like protein 4, Lin-28 homolog A, epithelial membrane antigen, and S100. Molecular studies revealed biallelic frameshift mutations in the SMARCB1 gene (c.673delG and c.683dupT) without pathogenic copy number aberrations. The histologic, immunohistochemical, and molecular findings support a diagnosis of MRT. The unusual age, location, and mutations of this case expand the clinicopathologic and molecular spectrum of MRT.


2019 ◽  
pp. 1-3
Author(s):  
Tamadur Mahasneh ◽  
Ali Al-Daghmin ◽  
Khloud Al-Qasem ◽  
Sayel H. Zraikat ◽  
Sohaib Alhamss

Malignant rhabdoid tumor was first thought to be a subtype of wilm’s tumor, which was later disproven by Haas et al. and was categorized as a separate entity. Malignant rhabdoid tumors are mainly present in the kidneys of children, however, cases of extra renal malignant rhabdoid tumor were reported in the literature. In this report we describe a case of extra renal malignant rhabdoid tumor in the adrenal gland. Malignant rhabdoid tumor is a highly aggressive neoplasm with very poor prognosis. Due to the rarity of the disease, no universal treatment regimen has been developed yet, where treatment options include the surgical removal of the tumor, chemotherapy, radiotherapy, or a multimodality approach of management. In this report we present a case of 21-year-old lady with MRT in the adrenal gland, who had neoadjuvant radio-chemotherapy followed by laparoscopic adrenalectomy.


2006 ◽  
Vol preprint (2007) ◽  
pp. 1
Author(s):  
Henry Krous ◽  
Amy Chadwick ◽  
Elisabeth Haas ◽  
Eric Breisch ◽  
Homeyra Masoumi

2006 ◽  
Vol preprint (2007) ◽  
pp. 1
Author(s):  
Lars Wagner ◽  
Jennifer Garrett ◽  
Edgard Ballard ◽  
D. Hill ◽  
Arie Perry ◽  
...  

2021 ◽  
pp. 109352662098649
Author(s):  
Tiffany G Baker ◽  
Michael J Lyons ◽  
Lee Leddy ◽  
David M Parham ◽  
Cynthia T Welsh

Rhabdoid tumor predisposition syndrome (RTPS) is defined as the presence of a SMARCB1 or SMARCA4 genetic aberration in a patient with malignant rhabdoid tumor. Patients with RTPS are more likely to present with synchronous or metachronous rhabdoid tumors. Based on the current state of rhabdoid tumor taxonomy, these diagnoses are based largely on patient demographics, anatomic location of disease, and immunohistochemistry, despite their nearly identical histologic and immunohistochemical profiles. Thus, the true distinction between such tumors remains a diagnostic challenge. Central nervous system atypical teratoid/rhabdoid tumor (AT/RT) is a rare, aggressive, primarily pediatric malignancy with variable histologic features and a well documented association with loss of SMARCB1 expression. Epithelioid sarcoma (ES) is a rare soft tissue tumor arising in patients of all ages and characteristically staining for both mesenchymal and epithelial immunohistochemical markers while usually demonstrating loss of SMARCB1 expression. To our knowledge we herein present the first documented case of a patient with RTPS who presented with metachronous AT/RT and ES.


2021 ◽  
Vol 16 (4) ◽  
pp. 815-818
Author(s):  
Dasic Ivana ◽  
Cvejic Sofija ◽  
Pavicevic Polina ◽  
Rancic Smilja

2014 ◽  
Vol 207 (9) ◽  
pp. 415-419 ◽  
Author(s):  
Kristopher R. Bosse ◽  
Aseem R. Shukla ◽  
Bruce Pawel ◽  
Kudakwashe R. Chikwava ◽  
Mariarita Santi ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Adel Attia ◽  
Moosa Suleman ◽  
Hesham Mosleh

Malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal malignancies in pediatric oncology. Malignant rhabdoid tumor was initially described in 1978 as a rhabdomyosarcomatoid variant of a Wilms tumor because of its occurrence in the kidney and because of the resemblance of its cells to rhabdomyoblasts. The absence of muscular differentiation led Haas and colleagues to coin the term rhabdoid tumor of the kidney in 1981, Haas et al..


2003 ◽  
Vol 194 (3) ◽  
pp. 303-313 ◽  
Author(s):  
Britta S. Reincke ◽  
Gary B. Rosson ◽  
Betty W. Oswald ◽  
Cynthia F. Wright

Sign in / Sign up

Export Citation Format

Share Document